Key result
Heart failure pharmacotherapy improves LVEF to 57% in congenital muscular ventricular septal aneurysm.
Why the study?
Congenital muscular ventricular septal aneurysm is rare, difficult to diagnose, and its therapeutic strategy and prognosis remain uncertain.
Does pharmacological treatment for heart failure improve cardiac function in a patient with congenital muscular ventricular septal aneurysm and reduced LVEF?
Case Report (n=1)
No
Does pharmacological treatment for heart failure improve cardiac function in a patient with congenital muscular ventricular septal aneurysm and reduced LVEF?
Pharmacological heart failure therapy may improve cardiac function in patients with congenital muscular ventricular septal aneurysm and reduced LVEF.
Background Muscular ventricular septal aneurysm (VSA) is commonly caused by myocardial infarction, myocarditis or trauma, but it may occasionally be congenital. For congenital VSA, the diagnosis is challenging, and the therapeutic strategy and prognosis remain uncertain. Case presentation A 32-year-old man was admitted following a detection of left ventricular aneurysm on echocardiography during a routine health checkup. The patient was asymptomatic, the echocardiography showed an aneurysm in the midventricular septum associated with regional hypokinesis, accompanied by left ventricular dilation and reduced left ventricular ejection fraction (LVEF) of 46%. Coronary computed tomography angiography and cardiac magnetic resonance localized the muscular VSA and revealed a cyst at the anteroinferior margin of the pericardium, further coronary angiography was unremarkable. Laboratory findings such as cardiac markers, rheumatologic, immunologic and inflammatory markers were within normal limits. The diagnosis of congenital muscular VSA coexisting with a pericardial cyst was considered. Pharmacological treatment for heart failure was initiated to prevent further reduction in LVEF. At the 3-month and 1-year follow-ups the patient remained asymptomatic, and echocardiography demonstrated the LVEF increased from 50% to 57%. Conclusion Congenital muscular VSA is an uncommon cardiac abnormality that may be accompanied by impaired cardiac function. Treatment for heart failure could improve the cardiac function.
No takes yet. Share an insight, caveat, or question.
Mou et al. (2026) conducted a case report in Congenital muscular ventricular septal aneurysm coexisting with a pericardial cyst (n=1). Heart failure medications (ACE inhibitor, beta-blocker, SGLT2 inhibitor) was evaluated on Left ventricular ejection fraction (LVEF). Pharmacological treatment for heart failure in a patient with a congenital muscular ventricular septal aneurysm improved left ventricular ejection fraction from 46% to 57% over 1 year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: